Skip to main content
Bloomberg Law

How Life Sciences Firms Can Reduce DOJ Enforcement Risks

May 6, 2021
Authors
Jaime L.M. JonesJack W. Pirozzolo

The Anti-Kickback Statute has long been a driver of enforcement actions against the life sciences industry. In this article, Sidley lawyers explore areas that are most likely to draw enforcement scrutiny and how compliance programs can be updated to control risk going forward.

View Article

Contacts

Jones, Jaime L.M.
合伙人律师
Pirozzolo, Jack W.
合伙人律师

Related Blogs

Capabilities

Suggested News & Insights

June DOJ/SBA FCA Settlements Highlight Continued Focus on Contractor ComplianceJuly 9, 2026
Original Source
Texas Supreme Court Imposes Materiality Requirement on Texas Healthcare Fraud Omissions ClaimsJuly 7, 2026
Original Source
Texas AG Secures Nearly $34 Million Settlement with Pharmaceutical Company, Reinforcing Active Ongoing THFPA EnforcementJuly 6, 2026
Original Source
HHS-OIG Decertifies New York Medicaid Fraud Control Unit, Escalating Federal Scrutiny of State Medicaid Fraud EnforcementJuly 6, 2026
Original Source
In House Hearing, DAAG Jenny Discusses FCA Enforcement Priorities Related to Grants, Faces Questioning on Using FCA to Target DiscriminationJune 29, 2026
Original Source
DOJ Reaches $507,144 Settlement with Defense Contractor, Signals Increased FCA Scrutiny of Cybersecurity Self-AssessmentsJune 23, 2026
Original Source